- Post-Effective Amendment to an S-8 filing (S-8 POS)
12 März 2009 - 11:03AM
Edgar (US Regulatory)
As
filed with the Securities and Exchange Commission on March 11, 2009
Registration
No. 33-
60576
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
POST-EFFECTIVE
AMENDMENT NO. 1 TO
FORM
S-8
REGISTRATION
STATEMENT
UNDER
THE SECURITIES
ACT
OF 1933
SYNVISTA
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
13-3304550
|
|
(State
or other jurisdiction
|
(IRS
Employer
|
|
of
incorporation or organization)
|
Identification
Number)
|
|
221
West Grand Avenue
Montvale,
New Jersey
(Address
of Principal Executive Offices)
|
07645
(Zip
Code)
|
|
|
|
ALTEON
INC. 1987 STOCK OPTION PLAN
|
|
(Full
title of the plan)
|
|
Noah
Berkowitz, M.D., Ph.D.
President
and Chief Executive Officer
|
Copies
to:
Megan
N. Gates, Esq.
|
|
Synvista
Therapeutics, Inc.
|
Mintz,
Levin, Ferris, Glovsky & Popeo, P.C.
|
|
221
West Grand Avenue
|
One
Financial Center
|
|
Montvale,
NJ 07645
|
Boston,
MA 02111
|
|
(201)
934-5000
|
(617)
542-6000
|
|
(Name,
address, including zip code, and telephone
number,
including area code, of agent for service)
|
|
DEREGISTRATION
OF UNSOLD SECURITIES
On April 2, 1993, Synvista
Therapeutics, Inc., formerly known as Alteon Inc. (the “Company”), filed a
registration statement on Form S-8 (File No. 33-60576) (the “Registration
Statement”). The Registration Statement registered a total of
2,865,600 shares of the Company’s common stock, par value $0.01 per share (the
“Common Stock”), to be issued pursuant to the Company’s 1987 Stock Option
Plan. This offering has been terminated because the Company intends
to deregister its Common Stock under the Securities Exchange Act of 1934, as
amended. Consequently, in accordance with an undertaking made by the
Company in the Registration Statement to remove from registration, by means of a
post-effective amendment, any of the securities that remain unsold at the
termination of the offering, the Company hereby removes from registration the
securities of the Company that are registered but unsold under the Registration
Statement.
SIGNATURES
Pursuant to the requirements of the
Securities Act of 1933, the registrant certifies that it has reasonable grounds
to believe that it meets all the requirements for filing on Form S-8 and has
duly caused this Post-Effective Amendment No. 1 to its Registration Statement to
be signed on its behalf by the undersigned, thereunto duly authorized, in the
City of Montvale, State of New Jersey on March 11, 2009.
|
|
SYNVISTA
THERAPEUTICS, INC.
|
|
|
|
|
|
/s/
Noah Berkowitz, M.D., Ph.D.
|
|
|
Noah
Berkowitz, M.D., Ph.D.
|
|
|
President
and Chief Executive
Officer
|
Pursuant to the requirements of the
Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration
Statement has been signed by the following persons in the capacities and on the
dates indicated.
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
|
/s/ Noah Berkowitz, M.D.,
Ph.D.
|
|
President, Chief Executive
|
|
March 11, 2009
|
|
Noah
Berkowitz, M.D., Ph.D.
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Wendy A. Milici
|
|
Principal Financial Officer
and
|
|
March 11, 2009
|
|
Wendy
A. Milici
|
|
Principal
Accounting Officer
|
|
|
|
|
|
|
|
|
|
/s/ John F. Bedard
|
|
Director
|
|
March 11, 2009
|
|
John
F. Bedard
|
|
|
|
|
|
|
|
|
|
|
|
/s/ William Federici
|
|
Director
|
|
March 11, 2009
|
|
William
Federici
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Mary C. Tanner
|
|
Director
|
|
March 11, 2009
|
|
Mary
C. Tanner
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Wayne P. Yetter
|
|
Director
|
|
March 11, 2009
|
|
Wayne
P. Yetter
|
|
|
|
|
S.Y. Bancorp (AMEX:SYI)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
S.Y. Bancorp (AMEX:SYI)
Historical Stock Chart
Von Nov 2023 bis Nov 2024
